Core Viewpoint - Zhuzhou Times New Material Technology Co., Ltd. is issuing shares to specific investors, with a total of 106,732,348 shares priced at 12.18 yuan per share, raising approximately 1.3 billion yuan for various projects and working capital [1][11]. Group 1: Issuance Details - The company is issuing domestic listed ordinary shares (A shares) with a par value of 1 yuan per share [3]. - The total number of shares to be issued is 106,732,348, with a total subscription amount of 1,299,999,998.64 yuan [7][11]. - The issuance price is determined based on a competitive bidding process, with the final price set at 12.18 yuan per share, which is 127.01% of the issuance base price [10][11]. Group 2: Shareholder Structure - After the issuance, Zhuzhou will remain the controlling shareholder, and CRRC Group will continue to be the actual controller of the company [1][12]. - The shares subscribed by CRRC Capital Holdings will be locked for 18 months, while other investors will have a lock-up period of 6 months [12] . Group 3: Use of Proceeds - The raised funds will be allocated to projects including the Innovation Center and Intelligent Manufacturing Base, Clean Energy Equipment Quality Improvement Project, and enhancement of capabilities for automotive vibration reduction products [11]. Group 4: Regulatory Compliance - The issuance has undergone necessary internal and external approval processes, including approval from the board of directors, shareholders' meeting, and the China Securities Regulatory Commission [4][9]. - The company has established a special account for the raised funds, with a tripartite supervision agreement in place to monitor the use of the funds [11].

证券代码：600458 证券简称：时代新材 公告编号：临 2025-032 ? 资产过户情况 重要内容提示： ? 发行数量和价格 股票种类：人民币普通股（A股） 株洲时代新材料科技股份有限公司（以下简称"时代新材"、"公司"、"发 行人"）已于 2025 年 7 月 11 日就本次向特定对象发行股票向中国证券登记结算 有限责任公司上海分公司办理完毕登记、托管及限售手续。 本次向特定对象发行新增普通股股份为有限售条件流通股，将于限售期届满 后的次一交易日起在上海证券交易所（以下简称"上交所"）上市流通交易，如 遇法定节假日或休息日，则顺延至其后的第一个交易日。自本次发行新增股份的 登记托管手续办理完成之日起，中车资本控股有限公司（以下简称"中车金控"） 认购的本次发行的 A 股股票 18 个月内不得转让，其他投资者认购的本次发行的 A 股股票 6 个月内不得转让。法律法规、规范性文件对限售期另有规定的，从其 规定。限售期结束后按中国证券监督管理委员会（以下简称"中国证监会"）及 上交所的有关规定执行。若前述限售期与证券监管机构的最新监管意见或监管要 求不相符，将根据相关证券监管机构的监管意见或监管要求进行相应调 ...

Group 1 - The company held its ninth meeting of the fourth Supervisory Board on July 14, 2025, with all three supervisors present, ensuring compliance with legal and procedural requirements [1] - The Supervisory Board approved the extension of the validity period for the resolution regarding the issuance of shares to specific targets by 12 months, allowing for the continuation of related work without changes to other aspects of the issuance [2] - The Supervisory Board also approved the extension of the authorization for the Board of Directors to handle matters related to the issuance of shares to specific targets for an additional 12 months, maintaining the same conditions as before [2] Group 2 - The company agreed to recognize an asset impairment provision of 18.4036 million yuan and to reverse a credit impairment provision of 3.9264 million yuan, resulting in a net reduction of 14.4772 million yuan in the consolidated profit total [3]

证券代码：600201 证券简称：生物股份 公告编号：临2025-041 金宇生物技术股份有限公司 关于终止2023年度向特定对象发行A股股票 并签署终止协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 金宇生物技术股份有限公司（以下简称"公司"）于 2025 年 7 月 14 日召开第 十二届董事会第二次会议，审议通过了《关于终止向特定对象发行股票并签署相关 终止协议的议案》，同意公司终止 2023 年度向特定对象发行 A 股股票（以下简称 "本次发行"），并与内蒙古金宇生物控股有限公司（以下简称"生物控股"）、张翀 宇先生、张竞女士签署《附条件生效的股份认购协议之终止协议》 （以下简称"《终 止协议》"）。现将具体情况公告如下： 一、公司本次向特定对象发行股票的基本情况 公司分别于 2023 年 2 月 7 日、2023 年 3 月 16 日召开第十一届董事会第五次 会议、第十一届监事会第四次会议、2023 年第二次临时股东大会审议通过了《关 于公司 2023 年度向特定对象发行股票方案的议案》等议案，股东大会授 ...

中信证券股份有限公司 关于 北方光电股份有限公司 向特定对象发行 A 股股票 发行过程和认购对象合规性的报告 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年七月 上海证券交易所： 北方光电股份有限公司（以下简称"光电股份""发行人"或"公司"）向 特定对象发行 A 股股票（以下简称"本次发行"）已获得中国证券监督管理委 员会（以下简称"中国证监会"）《关于同意北方光电股份有限公司向特定对象 发行股票注册的批复》（证监许可〔2025〕1044 号）同意注册批复。 中信证券股份有限公司（以下简称"中信证券""保荐人（主承销商）"或 "主承销商"）作为光电股份本次发行的保荐人（主承销商），根据《中华人民 共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下 简称"《证券法》"）《证券发行与承销管理办法》（以下简称"《发行与承销 管理办法》"）《上市公司证券发行注册管理办法》（以下简称"《注册管理办 法》"）《上海证券交易所上市公司证券发行与承销业务实施细则》（以下简称 "《实施细则》"）等相关法律、法规和规范性文件的规定、发行人董事会、股 东大会通过的与本次发行相关的决议及 ...

北方光电股份有限公司 截至 2025 年 7 月 8 日新增注册资本及股 本情况验资报告 信会师报字2025第 ZG12686 号 北方光电股份有限公司 截至 2025 年 7 月 8 日新增注册资本 及股本情况验资报告 目 录 页 次 一、 验资报告 1-2 二、 附件 1 3 附件 2 4 附件 3 5-6 验 资 报 告 信会师报字2025第ZG12686号 北方光电股份有限公司： 我们接受委托，审验了北方光电股份有限公司（以下简称"贵公司" "光电股份"）截至 2025 年 7 月 8 日止新增注册资本及股本情况。按照法 律法规以及协议、章程的要求出资，提供真实、合法、完整的验资资料， 保护资产的安全、完整是全体股东及贵公司的责任。我们的责任是对贵公 司新增注册资本及股本情况发表审验意见。我们的审验是依据《中国注册 会计师审计准则第 1602 号——验资》进行的。在审验过程中，我们结合贵 公司的实际情况，实施了检查等必要的审验程序。 贵公司原注册资本为人民币 508,760,826.00 元，股本为 508,760,826.00 元。根据贵公司第七届董事会第六次会议、第七届监事会第四次会议、2024 ...

Core Viewpoint - The company,卓越新能, is actively expanding its operations with significant investments in bioenergy projects and plans for stock issuance to raise funds for future growth [2][3]. Company Announcements -卓越新能 plans to invest 700 million RMB in a bioenergy production line project in Thailand, which includes a 300,000-ton biodiesel production facility and a combined production facility for 100,000 tons of HVO/SAF [2]. - The project will be implemented in phases, with the first phase focusing on the biodiesel production line, expected to be completed within 12 months [2]. - The company has obtained necessary approvals and is progressing with land exploration for the project [2]. -卓越新能 has revised its plan for a simplified stock issuance to specific investors, aiming to raise 300 million RMB, which does not require shareholder approval [3]. - The issuance is subject to approval from the Shanghai Stock Exchange and registration by the China Securities Regulatory Commission [3]. Financial Reports - A special audit report by利安达会计师事务所 confirmed the non-recurring gains and losses for卓越新能 for various periods, showing a net non-recurring gain of 6,545,072.29 RMB for Q1 2025 and a total of 14,166,526.58 RMB for the year 2024 [4]. - The report also highlighted previous years' losses, with 2023 showing a net loss of 29,444,833.12 RMB and 2022 a loss of 28,560,072.85 RMB [4].

Group 1 - The company, Fujian Guangshentang Pharmaceutical Co., Ltd., has received an inquiry letter from the Shenzhen Stock Exchange regarding its application for a private placement of shares [1][2] - The company has responded to the inquiry letter and updated its fundraising prospectus and related application documents [1] - The approval of the private placement is subject to review by the Shenzhen Stock Exchange and registration approval from the China Securities Regulatory Commission, with uncertainties regarding the outcome and timing [2] Group 2 - The company assures that the information disclosed is true, accurate, and complete, with no false records or misleading statements [1] - The company will fulfill its information disclosure obligations based on the progress of the private placement [2]

Core Viewpoint - The company is proposing to extend the validity period of the shareholder meeting resolution regarding the issuance of shares to specific targets by an additional twelve months to ensure the smooth progress of the issuance process [1][2][3]. Group 1: Meeting Details - The shareholder meeting is scheduled for July 18, 2025, at 14:00, hosted by Chairman Lai Chaohui [1]. - The agenda includes proposals to extend the validity period of the resolutions related to the issuance of shares to specific targets [1][2]. Group 2: Proposal Details - The company has previously held meetings on June 27, 2023, and July 25, 2023, to approve the issuance of shares to specific targets and to authorize the board to handle related matters [1][2]. - The current proposal aims to extend the validity period of the shareholder meeting resolution and the board's authorization for an additional twelve months, ensuring that the other terms of the issuance remain unchanged during this extension [2][3]. Group 3: Legal and Regulatory Framework - The proposals are in accordance with the Company Law, Securities Law, and relevant regulations governing the issuance of shares [4]. - The board seeks authorization to manage all matters related to the issuance, including adjustments to the issuance plan, pricing, and selection of investors [4].

Core Viewpoint - The company held the 21st meeting of the 7th Supervisory Board on July 11, 2025, to discuss and approve the proposal regarding the change of accounting firm and signing accountant for a specific stock issuance, along with related party transactions [1][2]. Group 1 - The meeting was convened in accordance with the Company Law of the People's Republic of China and the company's articles of association, with all five supervisors present [1]. - The proposal regarding the change of accounting firm and signing accountant was approved with a unanimous vote from the non-related supervisors, resulting in 3 votes in favor, 0 against, and 0 abstentions [1]. - Related supervisors recused themselves from the voting process to ensure compliance with regulations [1]. Group 2 - The detailed announcement regarding the stock issuance and related transactions will be published in major financial newspapers and on the official website for public access [2]. - The decision made during the meeting will be documented and available for review as part of the supervisory board's resolutions [2].